Press Center
Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results.
If you are a professional member of the media and would like to find out more about Priothera, please contact info@priothera.com.
Priothera receives a European Union grant of nearly € 685.000 for the development of its innovative treatment for hematologic cancers
As part of the 2021–2027 FEDER-FTJ-FSE+ Program for the Grand Est and Vosges Massif region. St-Louis, France – July 11, 2025 – Priothera, a late-stage biopharmaceutical company specializing in the development of innovative oncology treatments, today announces that it has secured funding of €684,939 from the Fondss pour une Transition Juste (FTJ) – Just Transition Fund – under the 2021–2027 FEDER-FTJ-FSE+ Program for the Grand Est and Vosges Massif region, managed by the Grand Est Regional Council.
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy. Saint-Louis, France and Dublin, Ireland – 24 June 2025– Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced that it has been awarded nearly €1.7 million in non-dilutive funding through the i-Nov innovation competition.
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
Saint-Louis, France and Dublin, Ireland – 3rd June 2025 – Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced the appointment of Dr. Hans Menssen, MD, PhD, BBA, to its Board of Directors.
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Saint-Louis, France and Dublin, Ireland – 6th May 2025– Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced the appointment of Jens Hasskarl, MD, PhD, as Chief Medical Officer (CMO).
Innover pour mieux soigner – Les cancers du sang avec Priothera
Florent Gros, Cofondateur et Président de Priothera, nous dévoile les ambitions de son entreprise spécialisée dans le traitement des hémopathies malignes, notamment la leucémie myéloïde aiguë (LMA). Entre innovation thérapeutique et défis d’une biotech en pleine croissance, il nous partage sa vision pour transformer les traitements et améliorer la survie des patients atteints de cancers du sang.
Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
Mocravimod is being investigated in a global MO-TRANS Phase III study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation...